Article Sidebar
Date Published:
01/06/2023
Abstract Views: 439
Views PDF: 136
Views PDF: 136
Issue
Section
Các bài báo
How to Cite
Lê, T. D. ., Ngô , V. H. ., & Nguyễn, D. H. . (2023). POST-EMBOLIZATION SYNDROME AFTER TRANSARTERIAL CHEMOEMBOLIZATION USING LIPIODOL TO TREAT HCC. Vietnam Medical Journal, 526(2). https://doi.org/10.51298/vmj.v526i2.5546
POST-EMBOLIZATION SYNDROME AFTER TRANSARTERIAL CHEMOEMBOLIZATION USING LIPIODOL TO TREAT HCC
Main Article Content
Abstract
Purpose: To evaluate the incident of Post-embolization syndrome (PES) and the factor influencing it in patients underwent TACE with lipiodol for treatment of HCC. Patient and methods: Patients underwent TACE in Viet Duc University Hospital from 08/2022 to 01/2023. Result: 235 patients with 324 TACEs were performed. The PES rate is 42.9%; the most frequent symptoms are fever (31.17%) and right upper abdominal quadrant pain (27.78%). Patients without selective lesion treatment and high chemical dosages had higher odds of developing PES (OR = 2.44 and 2.13, respectively). Conclusion: the selective TACE technique should be performed with a lower chemical dosage to minimize PES.
Article Details
References
1. Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209-249.
2. Green, S. and G.R. Weiss, Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Investigational New Drugs, 1992. 10(4): p. 239-253.
3. Lencioni, R., et al., Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology, 2016. 64(1): p. 106-16.
4. Blackburn, H. and S. West, Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer. Cancer Nurs, 2016. 39(5): p. E1-E18.
5. Siriwardana, R.C., et al., Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis. BMC Gastroenterology, 2015. 15(1): p. 96.
6. Chung, J.W., et al., Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology, 1996. 198(1): p. 33-40.
7. He, J.J., et al., Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization. J Cancer Res Ther, 2021. 17(3): p. 777-783.
2. Green, S. and G.R. Weiss, Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Investigational New Drugs, 1992. 10(4): p. 239-253.
3. Lencioni, R., et al., Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology, 2016. 64(1): p. 106-16.
4. Blackburn, H. and S. West, Management of Postembolization Syndrome Following Hepatic Transarterial Chemoembolization for Primary or Metastatic Liver Cancer. Cancer Nurs, 2016. 39(5): p. E1-E18.
5. Siriwardana, R.C., et al., Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis. BMC Gastroenterology, 2015. 15(1): p. 96.
6. Chung, J.W., et al., Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology, 1996. 198(1): p. 33-40.
7. He, J.J., et al., Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization. J Cancer Res Ther, 2021. 17(3): p. 777-783.